Roche immunotherapy combination increases lung cancer survival – study

(Reuters) – Roche’s immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim results of a late stage trial released on Wednesday.


Source: Reuters Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *